Aptinyx (APTX) Stock Price, News & Analysis

Company Overview

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Key Stats

• Today's Range: $0.09 to $0.10
• 50-Day Range: $0.06 to $0.10
• 52-Week Range: $0.01 to $0.72
• Volume: 231,126 shs
• Average Volume: 1.32 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

APTX Stock Analysis - Frequently Asked Questions

How were Aptinyx's earnings last quarter?

Aptinyx Inc. (NASDAQ:APTX) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.31).

When did Aptinyx IPO?

Aptinyx (APTX) raised $77 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What other stocks do shareholders of Aptinyx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aptinyx investors own include Plug Power (PLUG), Tesla (TSLA), Evofem Biosciences (EVFM), VBI Vaccines (VBIV), SCYNEXIS (SCYX), T2 Biosystems (TTOO) and ADMA Biologics (ADMA).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 9/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:APTX
• CIK: 1674365
• Web: www.aptinyx.com
• Phone: (847) 871-0377
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.57 per share
• Price / Book: 0.17

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.27